MYCN and neuroblastoma: Therefore, to directly test whether neuroblastoma with low expression of MYCN could derive a biological advantage from α4 integrin expression, we established stable cell lines ectopically expressing integrin α4 with a c-terminal GFP-tag in the MYCNlow (NB5) NB cell line [27–29] (Fig 2A).